Adeyinka Charles Adejumo1,2, Donghee Kim3, Umair Iqbal4, Eric R Yoo5, Brian C Boursiquot3, George Cholankeril3, Robert J Wong6, Paul Y Kwo3, Aijaz Ahmed3. 1. Department of Medicine, North Shore Medical Center, Salem, Massachusetts. 2. Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts. 3. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California. 4. Department of Medicine, Geisinger Medical Center, Danville, Pennsylvania. 5. Department of Internal Medicine, Santa Clara Valley Medical Center, San Jose, California. 6. Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, Oakland, California.
Abstract
Background/Aims: Patients with end-stage liver disease (ESLD) have a high risk for readmission. We studied the role of palliative care consultation (PCC) in ESLD-related readmissions with a focus on health care resource utilization in the United States. Methods: We performed a retrospective longitudinal analysis on patients surviving hospitalizations with ESLD from January 2010 to September 2014 utilizing the Nationwide Readmissions Database with a 90-day follow-up after discharge. We analyzed annual trends in PCC among patients with ESLD. We matched PCC to no-PCC (1:1) using propensity scores to create a pseudorandomized clinical study. We estimated the impact of PCC on readmission rates (30- and 90-day), and length of stay (LOS) and cost during subsequent readmissions. Results: Of the 67,480 hospitalizations with ESLD, 3485 (5.3%) received PCC, with an annual increase from 3.6% to 6.7% (p for trend <0.01). The average 30- and 90-day annual readmission rates were 36.2% and 54.6%, respectively. PCC resulted in a lower risk for 30- and 90-day readmissions (hazard ratio: 0.42, 95% confidence interval [CI]: 0.38-0.47 and 0.38, 95% CI: 0.34-0.42, respectively). On subsequent 30- and 90-day readmissions, PCC was associated with decreased LOS (5.6- vs. 7.4 days and 5.7- vs. 6.9 days, p < 0.01) and cost (US $48,752 vs. US $75,810 and US $48,582 vs. US $69,035, p < 0.01). Conclusion: Inpatient utilization of PCC for ESLD is increasing annually, yet still remains low in the United States. More importantly, PCC was associated with a decline in readmission rates resulting in a lower burden on health care resource utilization and improvement in cost savings during subsequent readmissions.
Background/Aims: Patients with end-stage liver disease (ESLD) have a high risk for readmission. We studied the role of palliative care consultation (PCC) in ESLD-related readmissions with a focus on health care resource utilization in the United States. Methods: We performed a retrospective longitudinal analysis on patients surviving hospitalizations with ESLD from January 2010 to September 2014 utilizing the Nationwide Readmissions Database with a 90-day follow-up after discharge. We analyzed annual trends in PCC among patients with ESLD. We matched PCC to no-PCC (1:1) using propensity scores to create a pseudorandomized clinical study. We estimated the impact of PCC on readmission rates (30- and 90-day), and length of stay (LOS) and cost during subsequent readmissions. Results: Of the 67,480 hospitalizations with ESLD, 3485 (5.3%) received PCC, with an annual increase from 3.6% to 6.7% (p for trend <0.01). The average 30- and 90-day annual readmission rates were 36.2% and 54.6%, respectively. PCC resulted in a lower risk for 30- and 90-day readmissions (hazard ratio: 0.42, 95% confidence interval [CI]: 0.38-0.47 and 0.38, 95% CI: 0.34-0.42, respectively). On subsequent 30- and 90-day readmissions, PCC was associated with decreased LOS (5.6- vs. 7.4 days and 5.7- vs. 6.9 days, p < 0.01) and cost (US $48,752 vs. US $75,810 and US $48,582 vs. US $69,035, p < 0.01). Conclusion: Inpatient utilization of PCC for ESLD is increasing annually, yet still remains low in the United States. More importantly, PCC was associated with a decline in readmission rates resulting in a lower burden on health care resource utilization and improvement in cost savings during subsequent readmissions.
Entities:
Keywords:
Nationwide Readmissions Database; cirrhosis; cost; length of stay
Authors: Issa J Dahabreh; Radley C Sheldrick; Jessica K Paulus; Mei Chung; Vasileia Varvarigou; Haseeb Jafri; Jeremy A Rassen; Thomas A Trikalinos; Georgios D Kitsios Journal: Eur Heart J Date: 2012-06-17 Impact factor: 29.983
Authors: Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Jasmohan S Bajaj; Chathur Acharya; Andrew Fagan; Melanie B White; Edith Gavis; Douglas M Heuman; Phillip B Hylemon; Michael Fuchs; Puneet Puri; Mitchell L Schubert; Arun J Sanyal; Richard K Sterling; Todd R Stravitz; Mohammad S Siddiqui; Velimir Luketic; Hannah Lee; Masoumeh Sikaroodi; Patrick M Gillevet Journal: Am J Gastroenterol Date: 2018-06-06 Impact factor: 10.864
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Raya E Kheirbek; Ross D Fletcher; Marie A Bakitas; Gregg C Fonarow; Sridivya Parvataneni; Donna Bearden; Frank A Bailey; Charity J Morgan; Steven Singh; Marc R Blackman; Michael R Zile; Kanan Patel; Momanna B Ahmed; Rodney O Tucker; Cynthia J Brown; Thomas E Love; Wilbert S Aronow; Jeffrey M Roseman; Michael W Rich; Richard M Allman; Ali Ahmed Journal: Circ Heart Fail Date: 2015-05-27 Impact factor: 8.790
Authors: Arpan A Patel; Anne M Walling; Joni Ricks-Oddie; Folasade P May; Sammy Saab; Neil Wenger Journal: Clin Gastroenterol Hepatol Date: 2017-02-04 Impact factor: 13.576
Authors: Justin K Brooten; Alyssa S Buckenheimer; Joy K Hallmark; Carl R Grey; David M Cline; Candace J Breznau; Tyler S McQueen; Zvi J Harris; David Welsh; Jeff D Williamson; Jennifer L Gabbard Journal: West J Emerg Med Date: 2020-07-08
Authors: Meghan Price; Elizabeth P Howell; Tara Dalton; Luis Ramirez; Claire Howell; Theresa Williamson; Peter E Fecci; Carey K Anders; Devon K Check; Arif H Kamal; C Rory Goodwin Journal: Neurooncol Pract Date: 2021-02-24